The increasing evidence for the clinical relevance of altered magnesium metabolism to states of altered insulin resistance confirms the role of magnesium deficit as a possible underlying common mechanism of the ''insulin resistance'' of hypertension and altered glucose tolerance. The pioneer work of Lawrence M. Resnick and his group using the cellular ion-based approach that we are only partially presenting here has consistently contributed to the progress of the field, demonstrating (a) the critical importance of magnesium metabolism in regulating insulin sensitivity as well as vascular tone, and blood-pressure homeostasis; (b) that magnesium deficiency, defined on the basis of intracellular free magnesium levels, and or serum ionized magnesium is a common feature of both diabetic and hypertensive states as well as various other cardiovascular and metabolic processes and aging; (c) the ability of environmental factors such as dietary nutrient-sugar and mineral content to alter the set point of steady-state cell ion activity; and (d) that magnesium supplementation is indicated in conditions associated with magnesium deficit although well-designed therapeutic trials of magnesium in essential hypertension and type 2 diabetes mellitus are needed in the near future.
INTRODUCTION
Increasing evidence have demonstrated a role for alterations of magnesium (Mg) metabolism in the pathophysiology of essential hypertension as well as of type 2 diabetes mellitus (DM2), and suggest the therapeutic potential of Mg supplementation in these conditions. This manuscript reviews the relationship of Mg metabolism with hypertension, insulin resistance, and DM2. In this task, I mostly focused on the work conducted by our group directed by my mentor and friend Lawrence M. Resnick, a pioneer of Mg research who I first joined in 1990 when he was working at the New York Hospital-Cornell University Medical Center in New York and that I have collaborated until his premature loss in 2004.
Mg AND HYPERTENSION
Although Mg was first recommended to lower blood pressure (BP) in patients with malignant hypertension as early as 1925, 1 old clinical studies have failed to demonstrate consistent abnormalities of serum Mg in essential hypertension. 2 Lawrence M. Resnick, in an article published in the New England Journal of Medicine in 1983, 3 observed that despite the fact that total serum Mg (MgT) levels in essential hypertensive subjects were indistinguishable from those of normotensive controls when they were considered as a homogeneous group, significant deviations in MgT levels were observed that correlated closely with levels of plasma renin activity. These observations suggested to him not only the importance of studying Mg metabolism in hypertensive subjects, but also that other measurements more specific and reliable than MgT measurement should be used to study Mg metabolism in these subjects. Ray K. Gupta, a PhD working at Albert Einstein College of Medicine in the Bronx, had recently demonstrated the possibility of 1 a precise and reliable determination of the intracellular free magnesium (Mgi) level in the human red blood cell by the 31 P-nuclear magnetic resonance ( 31 P-NMR) technique, 4 having demonstrated that the measured parameters are not sensitive to small pH changes that may occur within the cells, and the absence of any significant binding of Mg to hemoglobin in the red blood cells. 4, 5 NMR spectroscopic techniques are completely noninvasive and are still, at present, the gold standard for intracellular measurements of free Mg content. 5 We have recently extended our experience with the NMR technique to study cytosolic free Mg directly in situ, in vivo, and in human living tissues such as the muscle and brain. 6 The following year (1984), Lawrence M. Resnick and Ray Gupta, using this innovative 31 P-NMR technique that allowed them to precisely assess Mgi levels in red blood cells of human hypertensive subjects published in the Proceedings of the National Academy of Science USA a milestone paper on Mg research 7 in which 3 related key observations were made: (1) that individuals with essential hypertension had consistently lower levels of Mgi than did normotensive control subjects; (2) that the normalization of BP in hypertensive individuals was associated with levels of Mgi that were significantly higher than those of untreated hypertensive subjects and indistinguishable from those of normotensive control subjects; and (3) that a strong continuous inverse relationship was observed between Mgi and the height of BP, that is, the lower the Mgi, the higher the BP (Fig. 1 ). This close quantitative relationship between Mgi levels and hypertension was new and never appreciated before in studies of extracellular ion levels, and confirmed the existence of a pathophysiologic link between Mg depletion and human essential hypertension.
In the following years, using NMR spectroscopic techniques to noninvasively and coordinately analyze different steady-state intracellular ion concentrations, Resnick observed that metabolic conditions, including hypertension, metabolic syndrome, and diabetes, share a common altered intracellular environment, characterized at least in part by suppressed Mgi levels and reciprocally elevated levels of cytosolic free calcium (Cai) 7, 8 (Fig. 2) . Mg levels were found to be related not only to the height of BP but also to peripheral insulin resistance. 9 These common alterations of intracellular ionic species in different insulin-resistant conditions have supported the concept of an ionic basis underlying their frequent clinical coincidence (see below). The notion of altered Mg metabolism in hypertension was supported by previous experimental and epidemiologic observations. Mg ions, although not directly involved in the biochemical process of contraction, modulate VSM tone and contractility by affecting calcium ion concentrations and its availability at critical sites. Another pioneer of Mg research, Burton Altura and co-workers, in a series of studies, had demonstrated some years earlier that Mg ions directly influence baseline tension, vascular tone, and vascular responsiveness to pressor agents. 10, 11 Experimental dietary Mg deficiency may result in vasoconstriction, frank hypertension, potentiated atherosclerosis, and insulin resistance. [10] [11] [12] [13] Epidemiologic studies have suggested an inverse relationship between Mg intake and BP, lower dietary Mg intake being an independent predictor of hypertension. 14 Dietary Mg depletion in rats decreases serum Mg levels, and increases BP. 12 Our group, in an experimental rat model of hypertension, demonstrated that diets that raised or lowered Mgi, consistently lowered and raised, respectively, the BP, 15 and that urinary excretion of Mg and the Ca/Mg urinary ratio may be altered in secondary models of hypertension. 16 Other specific research of our group of altered cellular Mg metabolism in specific conditions includes salt-sensitive hypertension, preeclamsia, and aging. 
Salt-sensitive hypertension
To study the ionic basis of salt sensitivity in hypertension, we directly assessed the BP and intracellular ionic consequences of dietary salt loading in essential hypertensive subjects at extremes of salt intake, both in the presence and absence of concurrent therapy with the calcium channel-blocking agent, nifedipine. After studying hypertensive subjects on low (,50 meq/d) and high (.200 meq/d) NaCl diets for 1 month each, a salt-induced suppression of Mgi levels ( Fig. 3 ) with reciprocal Cai accumulation was observed in these subjects, and the ability of dietary salt to elevate BP in ''salt-sensitive'' hypertensive subjects was linked to these ionic changes. The relation of salt-induced pressure and ionic changes was continuous for all subjects, that is, the greater the salt-induced fall in Mgi, the greater the rise in Cai, and the more BP rose. Furthermore, the efficacy of the Ca-channel blockade to reverse salt-induced hypertension was related to its ability to reverse these ionic effects of salt loading, nifedipine reducing Cai and elevating Mgi levels. 17 These data emphasize the critical role of ionic changes in salt-sensitive hypertension, and suggest that dietary salt content may be one ''physiologic'' determinant of cellular ion activity and BP.
Preeclamsia
Although Mg sulfate is the drug of choice for reducing the rate of eclampsia and for preventing the recurrent convulsions in eclampsia, 18 a clear role of Mg deficiency in the pathophysiology of preeclampsia has not been clearly established. Recently, by applying the tissue NMR spectroscopic techniques to noninvasively measure Mgi levels directly in the muscles and brain of pregnant women, we have observed (1) that pregnancy itself is characterized by lower Mgi values both in the brain and muscle tissue; (2) that tissue Mg was further suppressed in preeclamptic women; and (3) that in brain tissue Mgi values were also quantitatively and inversely related to both systolic and diastolic BP 6 ( Fig. 4 ). 
Aging
We specifically studied the behavior of ion content with age and have showed a continuous age-dependent fall of Mgi with suppression in Mgi levels in peripheral blood cells of healthy elderly subjects 19 (Fig. 5 , upper panel). These alterations were not distinguishable from those occurring, independent of age, in essential hypertension or DM2 ( Fig. 5, lower panel) . In other terms, essential hypertension and/or DM2 appear to determine an acceleration of natural agedependent Mg depletion, suggesting that these ionic changes may be clinically significant, underlying the predisposition in elderly subjects to cardiovascular and metabolic diseases, and might therefore help explain the age-related increased incidence of these diseases.
At the same time, the naive concept of both hypertension and DM2 as diseases of accelerated vascular aging may be more literally true than previously thought, as both these diseases display the same ionic changes at all ages. Thus, having these conditions is ''ionically'' the same as getting older; for example, a 48-year-old patient with diabetes has cellular ionic alterations indistinguishable from a healthy 84-year-old, suggesting a role for Mg deficit in the increased incidence of hypertension and glucose intolerance with age. 20 Mg AND DIABETES Mg deficit and/or frank hypomagnesaemia in diabetic patients is a widely recognized finding. 21 Epidemiologic studies have found the high prevalence of hypomagnesaemia in subjects with DM2, especially in those with poorly controlled glycemic control, 22 and mean plasma Mg levels were significantly lower in diabetic patients than in control subjects, whereas 25% of the patients had values below those found in all control subjects. Ionized serum Mg (Mg ion) has been found to be more frequently reduced in DM2, and a Mg-ion depletion can be seen in many subjects with MgT still in the normal range. 23 At the cellular level, using gold-standard NMR techniques, our group has shown lower steady-state Mgi and reciprocally increased Cai levels 8, 24 in subjects with DM2, compared with nondiabetic subjects, and Mgi levels also quantitatively predict the fasting and post-glucose levels of hyperinsulinemia, as well as peripheral insulin sensitivity. Specifically, (a) fasting insulin levels 25 ; (b) the integrated insulinemic response to a standard oral glucose tolerance test 9 ; (c) the steady-state plasma glucose response to insulin infusion; and (d) M values for peripheral insulin sensitivity derived from euglycemic hyperinsulinemic clamps, are all inversely related to Mg levels, whether measured as Mgi in situ in brain, free, or total Mg in peripheral red blood cells. 26, 27 Furthermore, significant relationships are observed between Mgi and Cai levels and HbA1c, fasting blood glucose, and the glycemic response to oral glucose loading in normal, hypertensive, and diabetic subjects. 28 Both low Mg intake and increased Mg urinary losses have been associated with Mg deficit in diabetic subjects. 29, 30 Hyperglycemia and hyperinsulinemia may both have a role in the increased urinary Mg excretion contributing to Mg depletion. Independent of the cause of poor plasma and intracellular Mg content, a depletion of Mg seems to be a cofactor for a further derangement of insulin resistance. 31, 32 This is because at the biochemical level, Mg is required for both proper glucose use and insulin signaling. Intracellular Mg is a critical cofactor for several enzymes in carbohydrate metabolism, being a necessary cofactor in all ATP-transfer reactions, and because of its role as part of the activated MgATP complex required for all the rate-limiting enzymes of glycolysis, regulates the activity of all enzymes involved in phosphorylation reactions such as tyrosine-kinase and of all other protein kinases, all ATP and phosphate transferassociated enzymes, such as the CaATPases in plasma membrane and endoplasmic reticulum. Mg deficiency may result in disorders of tyrosine kinase activity on the insulin receptor, an event related to the development of a of postreceptorial insulin resistance and decreased cellular glucose use, 31, 32 that is, the lower the basal Mg, the greater the amount of insulin required to metabolize the same glucose load, indicating decreased insulin sensitivity. Specifically, in the skeletal muscle and fat tissue, insulin resistance would be the expected outcome in the presence of suppressed Mgi. Significant decrements in these enzyme activities can already be observed at the range of Mg values seen in disease states such as DM2 and hypertension. Thus, a deficient Mg status may both be a secondary consequence or may precede and cause insulin resistance and altered glucose tolerance, and even diabetes 27 (Fig. 6) . A Mg-deficient diet is associated with a significant impairment of insulin-mediated glucose uptake. 33 Recent epidemiologic data showing a significant inverse association between Mg intake and diabetes risk support the priority of Mg deficit. 34 The significant relations between fasting levels of Mgi levels to BP, fasting blood glucose, and peripheral insulin resistance also extend to structural indices of the cardiovascular system. Even in the absence of elevated BP suppressed Mgi levels are associated with increased echocardiographically measured posterior wall thickness and left ventricular mass index in both diabetic and/or hypertensive subjects 35 (Fig. 7) . When combined, hypertension in the presence of diabetes was associated with further deviated ion levels and a greater extent of cardiac hypertrophy. 35 Similarly, magnetic resonance imaging-determined values for aortic distensibility in normal and hypertensive humans were closely and positively related to concomitantly measured levels of Mgi measured in situ in the brain and skeletal muscle tissue by 31 P-NMR magnetic resonance spectroscopic techniques: the more suppressed the Mgi, the stiffer (less distensible) the aorta 36 (Fig. 8 ). Although these data suggest that Mgi content may determine clinically relevant biologic outcomes such as BP, cardiac mass, and cellular insulin responsiveness, 20 it is also concomitantly true that factors such as glucose and insulin may in turn, alter Cai and Mgi levels. Dynamically measuring Cai and Mgi after dietary salt (see above) or sugar loading allowed us to assess the role of different dietary circumstances in regulating BP and cellular ion metabolism. Specifically, the transient hyperglycemia of oral glucose loading reproduces in normal subjects the same altered ionic profile of depleted Mgi/increased Cai levels that occur chronically in diabetic subjects, 25, 17 which dynamically appear to be equally and inversely true for serum ionized Mg. The role of hyperglycemia in the Mgi depletion of diabetes has been confirmed by in vitro studies from our group where glucose in a specific, concentration-dependent and time-dependent manner, at concentrations achieved clinically, and independent of insulin lowered Mgi and reciprocally elevated Cai. 37 Barbagallo et al 38 reported that FIGURE 6 . Overall hypothesis in which intracellular magnesium deficiency may mediate the relationship between insulin resistance, type 2 diabetes (DM2), and hypertension. hyperglycemia alters ionic content also in VSMC, suggesting an ionic mechanism for the increased vasoconstriction present in chronic diabetic states. These glucose-mediated effects are independent of insulin action, as hyperglycemia induces these changes both in VSMC, and in red blood cells, where glucose transport is unaffected by insulin. 37, 39, 40 Insulin also has specific ionic effects to increase Mgi and Cai 41 as well as sodium. 40 This is a specific, dose-related action, independent of cellular glucose uptake. The overall hypothesis that Mgi content is a crucial determinant of cellular responsiveness is supported by other data from our group showing that the ability of insulin at physiologically maximal concentrations to stimulate Mgi is impaired in cells from hypertensive individuals, with reduced basal Mg levels, 42 confirming that insulin action is strictly dependent on the cellular Mg content; for all subjects, independent of their designation as normotensive or hypertensive, cellular Mg responsiveness to insulin or glucose was closely and directly related to basal cellular Mg levels-the lower the basal Mg, the less responsive was the cell to glucose or insulin. 42 Altogether, these data demonstrating ionic aspects of cellular insulin resistance have led us to hypothesize that the ''insulin resistance,'' currently defined by measurements of tissue glucose uptake, might equally well be defined on the basis of altered cellular ion responsiveness. Similar cellular behavior was found in cell responsiveness to glucose action. As was the case for insulin, the lower the Mgi, the less responsive is the cell to glucose. Thus, this ''ionic'' insulin resistance is probably not specific for insulin, but may rather be a tissue manifestation of a general property of cells in which steady-state Mgi and/or Cai levels may determine cell responsiveness to insulin, glucose, or other external stimuli. The importance of Mg to mediate insulin sensitivity is confirmed by other research of our group demonstrating that the action of the insulin mimetic substances vanadate and IGF-1 are both associated with a direct effect to stimulate Mgi levels, 43 and that the effects of antioxidants glutathione and vitamin E to improve glucose and insulin metabolism may derive at least in part from their action on Mg metabolism. Barbagallo et al 26 demonstrated that the action of glutathione and vitamin E to increase insulin sensitivity in hypertensive subjects is associated with a concurrent increase in Mgi, and that a significant direct relationship between glucose disposal increase and Mgi levels was present.
THE RESNICK IONIC HYPOTHESIS OF CARDIO-METABOLIC SYNDROME
What emerges from these data is an appreciation of the critical roles of steady-state ion activity in determining the set point of cellular function generally, and of dietary and hormonal factors in regulating the relation of extracellular to intracellular ions. Irrespective of their origin, the initiating contributions of genetic factors, and/or of dietary mineral or nutrient content, Resnick and coworkers considered most plausible that the above delineated cellular ionic alterations defined at least in part by suppressed Mgi levels and reciprocally excess steady-state Cai may underlie many of the pathophysiologic and clinical characteristics shared by hypertension, metabolic syndrome, frank diabetes, and aging. 20, 28, 44, 45, 46 These coordinate cellular ionic defects, if present more generally in different organ systems, would be expected, on the basis of what is already known, to produce a spectrum of altered tissue responses predisposing to disease states that may vary in their clinical appearance, presenting as either hypertension, diabetes, LVH, etc., according to which coinherited traits and environmental circumstances may predominate in that individual. The ''Resnick ionic hypothesis'', rather than focusing on a single organ defect leading to other defects in other tissues, emphasizes the primacy of a common cellular defect in ion handling, in explaining the various clinical manifestations of hypertension and diabetic vascular disease (Fig. 9) . Thus, hyperinsulinemia and insulin resistance do not ''cause'' hypertension. Neither does elevated BP ''cause'' insulin resistance. Rather, both phenomena derive from and are different tissue expressions of the same cellular ionic lesion. Specifically, in vascular tissue, deficient Mgi and increased Cai predispose to vasoconstriction and/or elevated BP, and in adipose and skeletal muscle, would result in insulin resistance. Similarly, altered cellular ion content in the heart would ultimately result in cardiac hypertrophy, in the kidney in altered renal ion excretion, 45 and in platelets would increase aggregability and thromboxane synthesis. 13 Altogether, these different individual tissue responses to this common underlying ionic defect would promote the onset of elevated BP, left ventricular hypertrophy, dysmetabolic states such as insulin resistance and DM2, and accelerated atherosclerotic vascular disease. We believe that the above Resnick ionic hypothesis represents a unifying concept, explaining the epidemiologic and clinical association of what in the past have been considered separate clinical entities, and what should more properly be considered part of an overall syndrome complex.
31

P-NMR SPECTROSCOPY AND Mg-SPECIFIC ION-SELECTIVE ELECTRODES AS DIAGNOSTIC TOOLS TO DEFINE THE Mg ''STATUS'' OF Mg-DEFICIENT SUBJECTS
One of the principle reasons why Mg metabolism has not become more the focus of routine attention in clinical practice has been the absence of an easily available, accurate, and reproducible measure of Mg status. Measurements of MgT levels, which include the protein-bound, chelated, and ionized fractions are not useful, and have proven inadequate for this purpose. MgT concentrations do not reflect the Mg status or intracellular pool, and cellular Mg or Mg-ion depletion can be seen with normal total serum concentrations. 23, 47, 48 Two technologies, 31 P-NMR spectroscopy and Mg-specific ion-selective electrodes, that measure intracellular and extracellular free levels of Mg, respectively, are a major advance in this regard. Using these techniques, a deficiency of intracellular and ionized extracellular Mg levels have been consistently demonstrated in both DM2, often when MgT levels were within normal limits. 23 Using Mg-selective ionselective electrodes, Resnick et al found that both Mg ion (0.552 6 0.008 vs. 0.630 6 0.008 mmol/L, P , 0.001) and Mgi (184 6 14 vs. 223 6 8 mmol/L, P , 0.001), but not MgT, were significantly reduced in DM2 subjects, with a close relationship being observed between Mg ion and Mgi (r = 0.728, P . 0.001). 23 Although the 31 P-NMR technique may remain a research-based test because of the expense and special requirements involved in setting up and maintaining the NMR equipment, the recent commercial development of an Mg-selective electrode apparatus ought to result in routine clinical use in the near future. Mg-ion levels are closely related to concurrently measured intracellular free Mgi values, 23 providing supplementary information about the distribution of Mg in intracellular and extracellular compartments. Measuring the ionized form of serum Mg is particularly important in subjects with DM2 and insulin-resistant states in which despite normal levels of MgT, 23 it is often possible to demonstrate an ionized hypomagnesaemia. Plasma MgT levels are a late indication of a depletion of cellular Mg stores, as the complexed serum Mg is the last store to be depleted when an already important Mg depletion may have occurred, while a declines in ionized unbound Mg ion may occur significantly earlier. Because Mg-ion levels are easy to determine and provide specific data on Mg deficiency, and Mg supplements can restore serum ionized Mg deficiency with a low rate of nonserious side effects, 27 it seems to be rational that diabetic patients should be routinely tested for serum Mg ion in order to diagnose a Mg deficit.
THERAPEUTICAL ROLE OF Mg SUPPLEMENTS IN Mg-DEFICIT CONDITIONS
The therapeutic role of Mg in DM2 and hypertension, although first reported over 80 years ago for malignant hypertension 1 and currently used in preeclamptic pregnancies, 18 (see above) remains unclear. Thus, even if a role for decreased Mg levels in the pathophysiology of hypertension appears likely, a consistent, reproducible effect of Mg supplementation on BP (besides preeclampsia) has not been confirmed in hypertension. Mg supplementation has been shown to decrease BP in many, 49, 50 but not in all clinical studies 51 and further data are needed to consider Mg as a nonpharmacologic tool for treating hypertension. Among the reasons for this are the virtual absence of adequately designed clinical trials of Mg therapy in hypertension or DM2, the differing treatment schedules used in a number of smaller clinical reports, and, most importantly, a failure to appreciate the heterogeneity of the underlying mechanisms contributing to diseases such as hypertension. In essential hypertension, as has already been the case for sodium and calcium, when the experimental design fails to a priori distinguish subjects on the basis of underlying pathophysiologic differences in, for example, plasma renin activity or other concurrent altered or deficient mineral metabolism, 52, 53 the results of a therapeutic trial will often be falsely modest. The effects of Mg supplements on the metabolic profile of DM2 subjects are also controversial, 54 benefits having been found in some, 55 but not in all clinical studies. 56 Differences in baseline Mg status and metabolic control may explain the differences among these studies. Thus, a recent clinical trial specifically conducted among DM2 with low MgT levels (index of an already advanced Mg deficit) found a beneficial effect of oral Mg supplementation on fasting and postprandial glucose levels and insulin sensitivity 54 and we have shown an improvement in insulin-mediated glucose uptake measured by euglycemic insulin clamp and a significant relationship between the parallel increase in plasma and erythrocyte Mg concentration and the progressive increase in the insulin sensitivity in DM2 patients who were supplemented with increased dosage of Mg supplements ( Fig. 10 ). 27 Among nondiabetic, apparently healthy subjects, there is also some evidence of relatively small but significant beneficial effects of Mg supplements on insulin sensitivity. 57 In a large epidemiologic study in which 85,060 women and 42,872 men, who had no history of diabetes or cardiovascular disease at baseline, had been followed, respectively, for 18 and 12 years, the risk for DM2 in the upper quintile of Mg intake, as compared with that in the bottom quintile, was about a third lower after adjustment for a number of potentially confounding variables; and a significant inverse association between Mg intake and diabetes risk. 34 Thus, taking into account that hypomagnesemia has been associated with an increased risk of developing glucose intolerance and diabetes, 21 the use of Mg supplements could be an alternative tool for the prevention of DM2, a hypothesis that needs to be confirmed by specific and well-designed trials with Mg. The fact that most but not all diabetic subjects have a Mg deficiency and that no large clinical trial has been specifically focused in subjects with a Mg deficit, diagnosed with an accurate and reliable technique (see above), may help explain the discrepancy between the unclear role of supplemental Mg on glycemic control in diabetics, and the significant impact on diabetes risk in prospective epidemiologic studies. 34 Thus, short-term and longerterm therapeutic trials of Mg in hypertension and diabetes mellitus are clearly needed in the near future. As we previously suggested, not only does the Mgdeficient status need to be assessed on the basis of specific and reliable tools but also metabolic balance studies of the interactive effects of Mg on renal sodium, calcium, and potassium handling are needed.
Altogether, with the recent advances in the accurate measurement of intracellular and ionized extracellular Mg levels, we have now the tools to translate what is already known of the critical importance of Mg in glucose and insulin metabolism and BP regulation into clinical routine, both in monitoring ionized Mg status and in therapeutically employing Mg in those conditions and in those subjects with Mg deficiency.
